Incomplete syllogisms as techniques of medicalization: The case of direct-to-consumer advertising in popular magazines, 1997 to 2003

Qualitative Health Research

Volumn 17, Issue 1, 2007, Pages 49-60

  Arney, Jennifer ^a   Rafalovich, Adam ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b PACIFIC UNIVERSITY   (United States)

Author keywords

Conditional syllogism; Direct to consumer advertising; Medicalization; Mental health; Mood disorders; Pharmaceuticals

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; FLUOXETINE; PAROXETINE; PSYCHOTROPIC AGENT; SERTRALINE; VENLAFAXINE;

ARTICLE; CONSUMER ADVOCACY; CONSUMER HEALTH INFORMATION; CONTENT ANALYSIS; DATA ANALYSIS; DRUG MARKETING; EMPATHY; MASS MEDIUM; MENTAL HEALTH; MOOD DISORDER; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; SELF EVALUATION;

ADVERTISING; ANTIDEPRESSIVE AGENTS; DRUG INDUSTRY; FEMALE; HUMANS; LOGIC; MALE; MOOD DISORDERS; PERIODICALS; PERSUASIVE COMMUNICATION;

EID: 33845468730     PISSN: 10497323     EISSN: 15527557     Source Type: Journal    
DOI: 10.1177/1049732306293778     Document Type: Article

References (38)

1. American Marketing Association. (2003). Consumers' attention to the brief summary in print direct-to-consumer advertisements: Perceived usefulness in patient-physician discussions. Journal of Public Policy and Marketing, 22, 181-181.
2. Belkin, L. (2001). Prime time pushers. Mother Jones, 26, 31-37.
3. Blaxter, M. (1978). Diagnosis as category and process: The case of alcoholism. Social Science and Medicine, 12, 9-17.
4. Bristol-Myers Squibb Company. (1997, June). Does your life have signs of persistent anxiety? Redbook, 172, 87-88.
5. Bristol-Myers Squibb Company. (1999, December 20). Isn't it time to get on top of your anxiety? People, 83-84.
6. Brown, P. (1995). Naming and framing: The social construction of diagnosis and illness. Journal of Health and Social Behavior, 35, 34-52.
7. Conrad, P. (1975). The discovery of hyperkinesis: Notes on the medicalization of deviant behavior. Social Problems, 23, 12-21.
8. Conrad, P., & Leiter, V. (2004). Medicalization, markets and consumers. Journal of Health and Social Behavior, 45, 158-176.
9. Conrad, P., & Potter, D. (2000). From hyperactive children to ADHD adults: Observations on the expansion of medical categories. Social Problems, 47, 559-582.
10. Conrad, P., & Schneider, J. W. (1980). Deviance and medicalization: From badness to sickness. Philadelphia: Temple University Press.
11. Eli Lilly and Company. (1998, May). Depression hurts. Reader's Digest, 153, 182-184.
12. Elliot, S. (2002, July 12). Pharmaceutical makers and ad agencies fight to preserve campaigns for prescription drugs. The New York Times, p. C2.
13. Food and Drug Administration Modernization Act of 1997. Pub. L. No. 105-115, 105th Cong.
14. Gill, V. T., & Maynard, D. W. (1995). On "labeling" in actual interaction: Delivering and receiving diagnoses of developmental disabilities. Social Problems, 42, 11-37.
15. Glaser, B. G. (1978). Theoretical sensitivity: Advances in the methodology of grounded theory. Mill Valley, CA: Sociology Press.
16. Glaser, B. G., & A. L. Strauss. (1967). The discovery of grounded theory: Strategies for qualitative research. Chicago: Aldine.
17. Glaxo Smith Kline Group of Companies. (2001, September 17). Millions could be helped by Paxil. Newsweek, 138, 22-24.
18. Lutfey, K. & Maynard, D. W. (1998). Bad news in oncology: How physicians and patients talk about death and dying without using those words. Social Psychology Quarterly, 61, 321-341.
19. Morris, L. (2001). Regulatory leapfrog. Pharmaceutical Executive, 21, 82-82.
20. National Institute for Health Care Management, Research and Educational Foundation. (2001, November). Prescription drugs and mass media advertising, 2000. Retrieved May 19, 2006, from http://www.nihcm.org/ DTCbrief.pdf
21. National Institute for Health Care Management, Research and Educational Foundation. (2002, March). Prescription drug expenditures in 2001: Another year of escalating costs. Retrieved May 19, 2006 from http:// www.nihcm.org/spending2001.pdf
22. National Institute of Mental Health. (2001). The numbers count: Mental disorders in America. Retrieved May 19, 2006, from http:// www.nimh.nih.gov/publicat/numbers.cfm
23. Parsons, T. (1951). The social system. New York: Free Press.
24. Pfizer. (2003, August). You know when you feel the weight of sadness. Ladies Home Journal, 120, 47-48.
25. Smith Kline Beecham Pharmaceuticals. (1999a, September 27). Has social anxiety put your life on hold? Time, 154, 29-29.
26. Smith Kline Beecham Pharmaceuticals. (1999b, December). Has social anxiety put your life on hold? Redbook, 174, 39-39.
27. Sokotch, M. (1998). Why DTC Rx advertising is no passing fad. Advertising Age, 69, 24-24.
28. Strauss, A. L., & J. Corbin. (1990). Basics of qualitative research: Grounded theory procedures and techniques. Newbury Park, CA: Sage.
29. Sutherland, M., & Sylvester, A. (2000). Advertising and the mind of the consumer: What works, what doesn't, and why (2nd ed.). St. Leonards, Australia: Allen & Unwin.
30. Thomaselli, R. (2003). DTC industry fears FDA pre-approval. Advertising Age, 74, 63-65.
31. United States General Accounting Office. (2002, October). Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations (GAO-03-177) [Report to congressional requestors]. Retrieved June 19, 2006, from http://www.gao.gov/new.items/d03177.pdf
32. Wilke, M. (1998). Prescription for profit. Advertising Age, 69, 12-12.
33. Williams, S. J., & Calnan, M. (1996). The "limits" of medicalization?: Modern medicine and the lay populace in "late" modernity. Social Science and Medicine, 42, 1609-1620.
34. Wolinsky, F. D., & Wolinsky, S. R. (1981). Expecting sick-role legitimation and getting it. Journal of Health and Social Behavior, 22, 229-242.
35. Woodcock, J. (2003, July 22). Direct to consumer advertising of prescription drugs: Exploring the consequences [Statement before the Senate Special Committee on Aging]. Retrieved May 19, 2006, from http:// www.fda.gov/ola/2003/AdvertisingofPrescriptionDrugs0722.html
36. Wyeth Pharmaceuticals. (2000, April 24). When suffering from depression or generalized anxiety disorder the true goal is to get well. Time, 155, 11-12.
37. Yuan, Y. & Duckwitz, N. (2002). Doctors and DTC. Pharmaceutical Executive, 22, 114-124.
38. Zola, I. K. (1966). Culture and symptoms - An analysis of patients' presenting complaints. American Sociological Review, 31, 615-630.